DICER1-associated central nervous system sarcoma: A comprehensive clinical and genomic characterization of case series of young adult patients

• Published in: Neuro-oncology practice Vol. 10; no. 4; pp. 381 - 390
• Main Authors: Cardona, Andrés F, Chamorro Ortiz, Diego Fernando, Ruíz-Patiño, Alejandro, Gomez, Diego, Muñoz, Álvaro, Ardila, Dora V, Garcia-Robledo, Juan Esteban, Ordóñez-Reyes, Camila, Sussmann, Liliana, Mosquera, Andrés, Forero, Yency, Rojas, Leonardo, Hakim, Fernando, Jimenez, Enrique, Ramón, Juan Fernando, Cifuentes, Hernando, Pineda, Diego, Mejía, Juan Armando, Rodríguez, July, Archila, Pilar, Sotelo, Carolina, Moreno-Pérez, Darwin A, Arrieta, Oscar
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01-08-2023
• Subjects: Original; brain neoplasms; DICER1; CNS sarcoma; next-generation sequencing; Ribonuclease III
• ISSN: 2054-2577; 2054-2585
• DOI: 10.1093/nop/npad014

Abstract
Background
DICER1 alterations are associated with intracranial tumors in the pediatric population, including pineoblastoma, pituitary blastoma, and the recently described “primary DICER1-associated CNS sarcoma” (DCS). DCS is an extremely aggressive tumor with a distinct methylation signature and a high frequency of co-occurring mutations. However, little is known about its treatment approach and the genomic changes occurring after exposure to chemoradiotherapy.
Methods
We collected clinical, histological, and molecular data from eight young adults with DCS. Genomic analysis was performed by Next-generation Sequencing (NGS). Subsequently, an additional germline variants analysis was completed. In addition, an NGS analysis on post-progression tumor tissue or liquid biopsy was performed when available. Multiple clinicopathological characteristics, treatment variables, and survival outcomes were assessed.
Results
Median age was 20 years. Most lesions were supratentorial. Histology was classified as fusiform cell sarcomas (50%), undifferentiated (unclassified) sarcoma (37.5%), and chondrosarcoma (12.5%). Germline pathogenic DICER1 variants were present in two patients, 75% of cases had more than one somatic alteration in DICER1, and the most frequent commutation was TP53. Seven patients were treated with surgery, Ifosfamide, Cisplatin, and Etoposide (ICE) chemotherapy and radiotherapy. The objective response was 75%, and the median time to progression (TTP) was 14.5 months. At progression, the most common mutations were in KRAS and NF1. Overall survival was 30.8 months.
Conclusions
DCS is an aggressive tumor with limited therapeutic options that requires a comprehensive diagnostic approach, including molecular characterization. Most cases had mutations in TP53, NF1, and PTEN, and most alterations at progression were related to MAPK, RAS and PI3K signaling pathways.